Edwards Lifesciences (EW) Expected to Release Earnings on Wednesday

Edwards Lifesciences (NYSE:EW) is anticipated to post its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect Edwards Lifesciences to announce earnings of $0.7370 per share and revenue of $1.68 billion for the quarter. Parties can check the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Wednesday, November 4, 2026 at 5:00 PM ET.

Edwards Lifesciences Stock Up 1.5%

Shares of NYSE EW opened at $93.38 on Tuesday. Edwards Lifesciences has a 12-month low of $74.66 and a 12-month high of $96.29. The company has a market capitalization of $53.77 billion, a PE ratio of 32.66, a price-to-earnings-growth ratio of 2.40 and a beta of 0.87. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.52 and a quick ratio of 3.77. The firm’s 50-day moving average is $88.22 and its two-hundred day moving average is $85.47.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the stock. JPMorgan Chase & Co. upped their price objective on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the company an “overweight” rating in a research note on Friday, October 2nd. Wall Street Zen lowered shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research report on Saturday. Argus lifted their target price on shares of Edwards Lifesciences from $105.00 to $115.00 and gave the stock a “buy” rating in a research note on Friday, August 21st. Truist Financial boosted their price target on Edwards Lifesciences from $90.00 to $95.00 and gave the company a “hold” rating in a report on Thursday, July 16th. Finally, Robert W. Baird cut their price target on Edwards Lifesciences from $94.00 to $90.00 and set a “neutral” rating for the company in a report on Thursday, October 15th. One research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and seven have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $101.16.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, SVP Andrew M. Dahl sold 544 shares of the stock in a transaction that occurred on Monday, August 31st. The shares were sold at an average price of $91.06, for a total value of $49,536.64. Following the completion of the sale, the senior vice president owned 14,868 shares of the company’s stock, valued at $1,353,880.08. This trade represents a 3.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Daniel J. Lippis sold 619 shares of the firm’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $92.03, for a total value of $56,966.57. Following the sale, the vice president owned 40,034 shares of the company’s stock, valued at $3,684,329.02. This represents a 1.52% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 5,045 shares of company stock worth $451,596. 0.31% of the stock is currently owned by corporate insiders.

Key Edwards Lifesciences News

Here are the key news stories impacting Edwards Lifesciences this week:

• Positive Sentiment: The PROGRESS trial found Edwards’ transcatheter aortic valve replacement (TAVR) was superior to clinical surveillance in moderate aortic stenosis patients with at-risk features, reducing the two-year composite of death or heart-failure events. The results support using TAVR earlier in the disease course and could expand the addressable patient population beyond severe aortic stenosis. PROGRESS Trial results
• Positive Sentiment: The CLASP II TR trial showed Edwards’ PASCAL system for tricuspid repair outperformed medical therapy alone on its six-month primary endpoint. The system also produced significant and sustained reductions in tricuspid regurgitation and improvements in patients’ quality of life through one year, strengthening the case for Edwards’ transcatheter tricuspid-repair franchise. CLASP II TR trial results
• Positive Sentiment: Bank of America analyst Travis Steed revisited Edwards following the PROGRESS data, highlighting the trial’s potential to support TAVR expansion in selected moderate aortic stenosis patients. Analyst attention reinforces the potential commercial significance of the results. Bank of America analyst coverage
• Neutral Sentiment: The longer-term stock impact will depend on regulatory decisions, guideline changes, reimbursement and physician adoption. The trial results are encouraging, but expanded indications would require additional execution before translating into revenue.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation (NYSE:EW) is a medical technology company focused on therapies for structural heart disease and critical care. The company develops and manufactures products designed to treat conditions affecting the heart’s valves, including aortic, mitral and tricuspid valve disorders.

Its portfolio includes transcatheter aortic valve replacement systems, transcatheter mitral and tricuspid therapies, surgical heart valves and valve-repair technologies. Edwards also provides related delivery systems and other medical devices used by physicians in minimally invasive and open-heart procedures.

Founded in 1958 by Miles Lowell Edwards, the company is headquartered in Irvine, California, and serves healthcare providers and patients internationally.